ADVERTISEMENT
Metastatic Breast Cancer Updates From the 2021 San Antonio Breast Cancer Symposium
J Clin Pathways. 2022;8(1):26-27.
December 7-10, 2021; San Antonio, Texas and Virtual.
The San Antonio Breast Cancer Symposium (SABCS), started in 1977, aims to deliver the latest information on breast cancer research to an international audience of academic and private physicians and researchers. The 2021 SABCS offered both a unique opportunity for participants to attend in-person or virtually.
The schedule featured sessions on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant disease. The program included formal lectures, interactive presentations, and panel and case discussions by leading breast cancer specialists from around the world.
Additional Journal of Clinical Pathways coverage of the 2021 SABCS can be found online.
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
Budget Impact of Blood-based Biomarker Assay in Patients With Metastatic Breast Cancer
Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the 2021 San Antonio Breast Cancer Symposium.
Third-line Chemotherapy With or Without Trastuzumab-based Therapy for Metastatic Breast Cancer
The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.
Oncologists’ Perspectives on Patient-centered Dosing for Metastatic Breast Cancer
Medical oncologists reported that a high percentage of patients experience distressing toxicity, a need for acute care, and dose interruptions with standard delivery of therapy for metastatic breast cancer.
